Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indicationDecember 15, 2021Psoriatic Arthritis
Guselkumab’s efficacy, safety confirmed in patients with psoriatic arthritis and prior TNFi exposureDecember 2, 2021Psoriatic Arthritis
TNF-α inhibitor remains a promising therapy for nail psoriasis and concomitant PsANovember 30, 2021Psoriatic Arthritis
Upadacitinib improves PRO in PsA patients with inadequate response to non-bDMARDNovember 30, 2021Psoriatic Arthritis
No impact of COVID-19 pandemic on prevalence of depressive symptoms in patients with PsANovember 30, 2021Psoriatic Arthritis
PsA: Ixekizumab more effective than adalimumab irrespective of concomitant psoriasis severityNovember 30, 2021Psoriatic Arthritis
Guselkumab shows long-term safety and efficacy in biologic-naive patients with PsANovember 30, 2021Psoriatic Arthritis
Swollen joints better predict ultrasound-defined inflammation in PsA than tender jointsNovember 30, 2021Psoriatic Arthritis
Risk for serious infection lower in patients with PsA vs. RA treated with TNF inhibitorsNovember 30, 2021Psoriatic Arthritis
PsA: Long-term benefits of upadacitinib in patients with inadequate response to biologicsNovember 30, 2021Psoriatic Arthritis
Serious infection hospitalizations have declined in patients with PsANovember 19, 2021Psoriatic Arthritis
Tofacitinib postmarketing trial data shed light on JAK inhibitor risksNovember 16, 2021Psoriatic Arthritis
